AstraZeneca

Architects' plans for the Nottingham, UK facility

$47m innovation facility built in Nottingham, UK

By Fiona BARRY

The UK’s BioCity in Nottingham is adding a £30m ($47m) facility to house life science start-ups including CROs. The site will also become a hunting ground for a soon-to-launch venture capital fund which will invest in the SME tenants.

Roundup of new CRO tech, research collaborations and more

Roundup of new CRO tech, research collaborations and more

By Zachary Brennan

The 51st annual DIA conference in Washington, DC has been abuzz all week with new offerings from the top CROs (contract research organizations), in addition to new collaborations between top sponsors and academic institutions. Here’s a rundown of the...

CROs look to buttress research models businesses with CRISPR/Cas tech

CROs look to buttress research models businesses with CRISPR/Cas tech

By Zachary Brennan

As the largest pharma and tech suppliers – from Novartis to GE Healthcare to Thermo Fisher – begin exploring the world of CRISPR/Cas gene editing technology, contract research organizations are also looking into the new tech to explore ways to help clients’...

Experts discuss the impact of M&A on CRO, sponsor partnerships

Dispatches from PCT US

Experts discuss the impact of M&A on CRO, sponsor partnerships

By Zachary Brennan

As M&A continues to ramp up for the pharma and biotech industry, communication and agility are two of the major keys for CROs to adapt to an acquisition, experts said Thursday at the Partnerships in Clinical Trials Conference in Boston.

Quintiles, Parexel, PPD lead all CROs in US trial totals, review finds

Quintiles, Parexel, PPD lead all CROs in US trial totals, review finds

By Zachary Brennan

CROs (contract research organizations) continue to collaborate with sponsors on more clinical trials in the US, though the largest companies, such as Quintiles, Parexel and PPD, are working on a much larger share of the research as collaborators than...

CFDA accepts WuXi-MedImmune’s IND for new mAb

CFDA accepts WuXi-MedImmune’s IND for new mAb

By Zachary Brennan

The China Food and Drug Administration (CFDA) has accepted for review an Investigational New Drug (IND) application for WuXi and MedImmune's novel anti-IL6 monoclonal antibody (mAb) for rheumatoid arthritis.